Prescient Therapeutics Ltd (PTX.AX) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Australia · ISIN AU000000PTX3
Prescient Therapeutics Ltd financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 4.36 m AUD | – |
| Gross profit | 4.36 m AUD | -110,343.00 AUD |
| Operating income | -7.54 m AUD | -10.59 m AUD |
| EBIT | -7.54 m AUD | -10.59 m AUD |
| Net income | -7.32 m AUD | -7.00 m AUD |
| Diluted EPS – continuing operations | -0.01 AUD | -0.01 AUD |
Full history since 1989, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Prescient Therapeutics Ltd
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first-in-class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company is also developing cell therapy platforms, including CellPryme, a high-performance cell therapy enhancement platform; and OmniCAR, is a platform seeks to overcome the challenges of conventional CAR-T therapy including manufacturing, safety and reliability. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
More stocks
- BLUEMTEC Co., Ltd. (439580.KQ)
- Scienjoy Holding Corp (SJ)
- Gold Rain Enterprises (4503.TWO)
- Kingray Technology Co., Ltd. (6787.TWO)
- Pentech Holdings Berhad (0457.KL)
- Pacgold Ltd (PGO.AX)
- INTERLINK ELECTRONICS INC (LINK)
- Walrus Pump Co., Ltd. (6982.TWO)
- Synbio Tech Inc. (1295.TWO)
- Marathon Bancorp, Inc. /MD/ (MBBC)
- Laredo Oil, Inc. (LRDC)
- Grove Collaborative Holdings, Inc. (GROV)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.